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fracture risk for any fractures (AF), hip fractures (HF), vertebral fractures (VF), and
non-vertebral fractures (NVF) separately, controlling for patient characteristics,
insurance type, health care provider type, Charlson comorbidity index score, pre-
index bone mineral density test, medication use and fracture history. RESULTS:
Among the 3587 new TPTD users (mean age 68.9 years; 91% female), adjusted inci-
dence rates per 1000 patient years by fracture type (for persistence groups 1-6months,
7-12months, 13-18months, 19-24months)were: AF 103.09, 78.17, 72.68, 59.31; HF 6.87,
6.11, 4.30, 3.76; VF 26.29, 15.62, 11.55, 9.57; and NVF 70.90, 60.29, 60.24, 48.60. Fracture
risk was significantly higher for persistence 6 months versus 19-24 months in all
fracture models (OR1.75 [AF], 2.67 [VF], and 1.41 [NVF]), except for HF (OR1.95,
p0.078). Other significant risk factors included: older age (HF (OR1.06, p0.001) and
VF (OR1.04, p0.001); previous anticonvulsant use (VF (OR2.20, p0.001), VF
(OR1.79, p0.001)); previous immunosuppressant use (NVF (OR1.54, p0.013)); and
pre-index fracture (AF (OR1.37, p0.005); NVF (OR1.71, p0.001)). CONCLUSIONS:
Among US teriparatide patients, fracture incidence rates and fracture risk decreased
as persistence increased for any clinical, vertebral, and non-vertebral fractures.
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OBJECTIVES: to investigate the association between persistence with bisphospho-
nates therapy and the risk of hip fracture in a large cohort of adult women.
METHODS: A retrospective cohort study using the database of Maccabi Healthcare
Services, a 2-million member health maintenance organization in Israel. Persis-
tence with bisphosphonates therapy was assessed by calculating the proportion of
days covered (PDC). Patients included women aged 60 years or above initiating an
oral bisphosphonates for osteoporosis between 2002 and 207. RESULTS: The inci-
dence density rate of hip fractures during study follow-up period was 4 per 1000
person-years among the 8741 patients meeting study eligibility criteria. We found
an inverse relation between persistence with bisphosphonates and hip fracture
rate. Women covered with bisphosphonates for at least 75% of the time, had a
hazard ration of 0.65 (95% confidence interval: 0.05-2.3) for hip fracture, compared
to women covered with bisphosphonates for less than 25% of the time..
CONCLUSIONS:We found a suggestive negative relation between persistence with
osteoporosis treatment and long term risk of hip fracture.
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OBJECTIVES: To estimate the prevalence and risk factors associated with fracture
events in osteoporosis patients using proton pump inhibitor (PPI) therapy.
METHODS: This analysis utilized data from the 2001-2008 Medical Expenditure
Panel Surveys. Patients were identified if they were 50 years old, reported
having osteoporosis (ICD-9-CM code of 733 or clinical classification of 206). The
identified patients were classified into two groups depending on use of PPI.
Medications considered were osteoporosis medications (e.g., bisphosphanates,
hormone therapy, and raloxifene) and corticosteroids (excluding topical formu-
lations). Fractures were identified based on ICD-9-CM codes of 804-829. Preva-
lence of fractures was compared between two groups. Factors influencing risk of
fracture were identified through multivariable logistic regression after adjust-
ing for patient characteristics, use of medications, and comorbidities such as
heart disease, hypertension, nephropathy, depression, arthritis, epilepsy, dia-
betes, stroke, and cancer. RESULTS: We identified 4,979 patients with osteopo-
rosis, of which 970 were using PPIs and 4,009 patients were not. The majority of
the study patients were composed of females (91.4%) and non-smokers (89.6%).
Corticosteroids were used in 20.7% of the patients and osteoporosis medications
in 61.8% of patients. Bisphosphonates were the most commonly used agent in
49.2% of patients. Fractures were more prevalent in patients with PPI compared
to patients without (11.3% vs. 7.5%; p.003). Patients with PPI had a higher
likelihood of having a fracture than patients without PPI (OR1.53; p.009).
Other factors increasing risk of fractures were increasing age, heart disease,
hypertension, and stroke. CONCLUSIONS: PPI use in osteoporosis patients in-
creased the prevalence and risk of fractures. The results add to the growing body
of evidence supporting increased risk of fractures in osteoporosis patients
treated with a PPI. Additional research is recommended to investigate incidence
of fracture caused by use of PPI in osteoporosis patients.
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OBJECTIVES: Patientswith Rheumatoid Arthritis (RA) experience excess cardiovas-
cular (CVD) morbidity andmortality. RA puts patients at twice the risk for myocar-
dial infarction (MI) and stroke, younger patients being at higher risk.We investigate
the impact of RA on CVD morbidity in a high risk Medicaid managed care popula-
tion, largely female, African American, young adults, with baseline risk factors of
hypertension and diabetes. METHODS: Maryland Medicaid claims data for pa-
tients with diabetes and/or hypertension, from January 2001-June 2006 were
analyzed. Using exploratory analysis, we assessed the prevalence of RA and of
CVD, as well as the prevalence of CVD within the RA population. Logistic regres-
sion analysis was used to explore the joint impact of RA, demographics, hyper-
tension and diabetes on the likelihood of having a CVD event. RESULTS: The
prevalence RA was 2.2% among patients at high-risk for CVD. Patients with RA
were significantly older (mean age 49 vs. 34, p0.0001), largely females (80% vs.
64%, p0.0001) and non-African American (55% vs. 59%, p0.0001) than those
without RA. CVD prevalence was significantly higher in the RA population
among compared to the general population (37% vs. 17%). After adjusting for
demographics (age, gender, race) and risk factors (hypertension, diabetes), RA
significantly increased the likelihood of CVD events (OR: 1.539, 95% CI: 1.416-
1.674). In the adjusted model, hypertension (OR: 3.227) and diabetes (OR: 2.035)
also independently increased the likelihood of CVD events. CONCLUSIONS: We
found that RA independently increased cardiovascular risk by 1.5 times, in a Med-
icaid population with high baseline risk.
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OBJECTIVES: To evaluate the budget impact of adherence to concomitant gastro-
protective (GPA) therapy among patients using non-selective non-steroidals (ns-
NSAIDs) or COX-2 inhibitors (COXIBs) at high risk for NSAID-induced upper gastro-
intestinal (UGI) complications. Clinical guidelines recommend that patients at high
risk for UGI complications using ns-NSAIDs or COXIBs for arthritis pain manage-
ment should concomitantly take GPA; however, GPA use and adherence are often
low and associated with an increase in UGI events.METHODS: The impact of GPA
adherence was assessed using a budget impact model with a one-year time hori-
zon. UGI risk is a function of patient (age, previous ulcer history, concomitant low
dose aspirin use) and treatment (ns-NSAID or COXIB, concomitant GPA use and
adherence) characteristics. A mean GPA adherence rate of 51% was derived from
theMarketScan Research Databases, using a sample of patients50 years old with
at least 2 prescriptions for ns-NSAIDs or COXIBs from 2001 through 2007
(N738,248). Treatment-specific UGI event rates and costs were taken from the
literature for dyspepsia, symptomatic ulcers and UGI bleeding. Sensitivity analysis
was performed around the model inputs. RESULTS: In the base case analysis,
NSAID-induced UGI events are responsible for $9,328,857 in direct medical costs
annually in a hypothetical health plan with 100,000 members, where 21.6% of
patients are on chronic ns-NSAID or COXIB therapy for arthritis and 82% of these
patients are at increased risk of a UGI event due to age, previous ulcer history, or
both. Increasing GPA adherence to 75% decreases NSAID-induced UGI event costs
by $547,074, or -$0.45 per-member-per-month (PMPM) in a 100,000-member health
plan; reducing GPA adherence to 25% increases these costs by $737,834 ($0.62
PMPM). CONCLUSIONS: GPA adherence has a strong impact on the cost associated
with NSAID-induced UGI events. This finding was consistent throughout sensitiv-
ity analyses varying risk factors and costs of UGI events.
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OBJECTIVES: In 2009, the price of colchicine, an anti-gout agent that is also used to
treat familial Mediterranean fever, skyrocketed, surprising physicians, patients,
and payers. Objectives are to (1) determine the cost consequence to the U.S. Med-
icaid programs of this price rise and (2) explain why it occurred. METHODS: Med-
icaid drug utilization data were used to identify all colchicine products from 2000
quarter 1 through 2010 quarter 1. The first five digits of each product’s NDC code
were used to identify the manufacturer. A retrospective, descriptive analysis was
conducted to determine the trends of colchicine utilization (prescriptions and tab-
lets), spending (in 2009 US$), and reimbursement per tablet as a proxy for price.
RESULTS:Colchicine utilization byMedicaid enrollees increased from 2000 to 2005,
reaching 417,000 prescriptions (18million tablets, $4.5million). FollowingMedicare
Part D and the movement of dual eligibles from Medicaid to Medicare, Medicaid
colchicine utilization dropped 72% in terms of number of prescriptions. The aver-
age spending for colchicine not marketed by URL Pharma increased from $0.27 per
tablet in 2000–2009 to $0.35 in the first quarter of 2010 (30% increase), while the
Colcrys® price (URL’s branded drug) rose from $0.29 in 2000–2008 to $3.79 in 2009–
2010 (12-fold increase). It is estimated that an additional $21million could be added
to Medicaid spending if all patients on single-ingredient colchicine treatment
switched to Colcrys®. CONCLUSIONS: The rise in price is an unintended conse-
quence of a drug-safety initiative launched in June 2006 by the U.S. Food and Drug
Administration (FDA) to phase out unapproved drugs, including single-ingredient
oral colchicines. Meanwhile, the FDA granted approval to URL Pharma in July 2009,
inadvertently creating a monopoly in the anti-gout market. If additional drugs are
not approved to stimulate competition, a substantial financial burden will be
placed on patients and taxpayers.
PMS11
APPLYING THE STRATIFIED PROPENSITY SCORE MATCHING METHOD WHEN
ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS
Baser O, Xie L
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To apply the stratified propensity score matching technique to esti-
mate the healthcare costs of rheumatoid arthritis (RA) patients. METHODS: Con-
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